Ongoing Research and Development Activities
First written in FY2022-Q3. 8 of 13 entries say "Restated". Latest entry: FY2026.
34 other companies' latest entry also says "Advanced".
- FY2026AdvancedAnnual report
「As 2 contract development products that had been under development were successfully launched, the company is advancing initiatives to expand its range of new GMP intermediates and identify the next large-scale products. It is particularly focused on developing new customers and securing projects, including in new modalities beyond small-molecule pharmaceuticals.」
The report describes the launch of 2 contract development products and concrete progress toward mass production and commercialisation, including the operation of a 30L glass bench-scale plant and the introduction of trace-metal control equipment and an ICP-MS/MS analysis room. Meanwhile, the Shonan Innovation Research Institute was closed in September 2025. - 2026-05-14AdvancedRevision to earnings forecast
「また、半導体関連製品等の新規開発品目が進んでおり、これらの要因により売上高及び利益ともに増加いたしました。」
半導体関連製品等の新規開発品目について、進展しているとの記載が加わった。 - FY2026-H1RestatedAnnual report
「The Group's total research and development expenditure for the six months ended 30 September of the current fiscal year was ¥178 million. There were no material changes in the status of the Group's research and development activities during the period.」
The company recorded research and development expenses of ¥178 million and stated that there were no material changes in the status of its research and development activities. - FY2025-H1RestatedAnnual report
「The Group's total research and development expenditure for the six months ended 30 September of the current fiscal year was ¥240 million. There were no material changes in the status of the Group's research and development activities during the period.」
The company recorded research and development expenses of ¥240 million and stated that there were no material changes in the status of its research and development activities. - FY2024AdvancedAnnual report
「In the development of pharmaceutical intermediates, 2 globally marketed products under contract development, both non-GMP, and an in-house-developed hypervalent iodine compound smoothly transitioned to a mass-production framework. Going forward, we will focus on initiatives to expand our GMP intermediate portfolio.」
The 2 globally marketed products and the hypervalent iodine compound transitioned to a mass-production framework. The report also describes the establishment of a technology development centre, the Shonan Innovation Research Institute, collaboration with universities and public research institutions, and research and development expenses of ¥468 million. - FY2024-Q3RestatedAnnual report
「The Group's total research and development expenditure for the nine months ended 31 December of the current fiscal year was ¥352 million. There were no material changes in the status of the Group's research and development activities during the period.」
The company recorded research and development expenses of ¥352 million and stated that there were no material changes in the status of its research and development activities. - FY2024-Q2RestatedAnnual report
「The Group's total research and development expenditure for the six months ended 30 September of the current fiscal year was ¥223 million. There were no material changes in the status of the Group's research and development activities during the period.」
The company recorded research and development expenses of ¥223 million and stated that there were no material changes in the status of its research and development activities. - FY2024-Q1RestatedAnnual report
「The Group's total research and development expenditure for the three months ended 30 June of the current fiscal year was ¥110 million. There were no material changes in the status of the Group's research and development activities during the period.」
The company recorded research and development expenses of ¥110 million and stated that there were no material changes in the status of its research and development activities. - FY2023-Q3RestatedAnnual report
「The Group's total research and development expenditure for the nine months ended 31 December of the current fiscal year was ¥252 million. There were no material changes in the status of the Group's research and development activities during the period.」
The company recorded research and development expenses of ¥252 million and stated that there were no material changes in the status of its research and development activities. - FY2023-Q2RestatedAnnual report
「The Group's total research and development expenditure for the six months ended 30 September of the current fiscal year was ¥165 million. There were no material changes in the status of the Group's research and development activities during the period.」
The company recorded research and development expenses of ¥165 million and stated that there were no material changes in the status of its research and development activities. - FY2023-Q1RestatedAnnual report
「The Group's total research and development expenditure for the three months ended 30 June of the current fiscal year was ¥84 million. There were no material changes in the status of the Group's research and development activities during the period.」
It recorded ¥84 million in research and development expenses and explains that there were no material changes in the status of research and development activities. - FY2022AdvancedAnnual report
「In addition, we newly established 3 research centres, the Gofun, Toyama and Shonan laboratories, to expand our business areas and invigorate the development of our proprietary products and technologies. Together with developing this research and development environment, we will pursue the creation of new businesses and our own strengths.」
The company established 3 research and development centres and recorded research and development expenses of ¥290 million for the consolidated fiscal year. It also provided details of development projects, including pharmaceutical intermediates, electronic materials and environmentally friendly flame retardants. - FY2022-Q3First statedAnnual report
「The Group's total research and development expenditure for the nine months ended 31 December of the current fiscal year was ¥215 million.」
The Group spent ¥215 million on research and development during the nine months ended 31 December of the current fiscal year.